<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">33465527</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>15</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-033X</ISSN><JournalIssue CitedMedium="Internet"><Volume>66</Volume><PubDate><Year>2021</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Current opinion in structural biology</Title><ISOAbbreviation>Curr Opin Struct Biol</ISOAbbreviation></Journal><ArticleTitle>SOD1 oligomers in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>225</StartPage><EndPage>230</EndPage><MedlinePgn>225-230</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.sbi.2020.12.002</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0959-440X(20)30218-9</ELocationID><Abstract><AbstractText>Identifying nonnative, trimeric forms of SOD1 trimers as the toxic species, rather than large aggregates revolutionizes our understanding of ALS pathophysiology. Large protein aggregates, what was previously thought as the central cause of neurodegeneration, play protective role and are not responsible for neuronal death. SOD1 trimers are implicated at the molecular, cellular, and organismal level. Understanding the formation of the nonnative trimer and its role in the cell, leading to cell death, holds the key to developing a new standard of therapeutics for ALS and for other neurodegenerative diseases. This review highlights recent advances of knowledge for the role of SOD1 oligomers in ALS.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Esther S</ForeName><Initials>ES</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Penn State College of Medicine, Hershey, PA, USA; Medical Scientist Training Program, Penn State College of Medicine, Hershey, PA, USA. Electronic address: euc504@psu.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dokholyan</LastName><ForeName>Nikolay V</ForeName><Initials>NV</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Penn State College of Medicine, Hershey, PA, USA; Department of Biochemistry and Molecular Biology, Penn State College of Medicine, Hershey, PA, USA. Electronic address: nxd338@psu.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R35 GM134864</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR002014</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>01</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Curr Opin Struct Biol</MedlineTA><NlmUniqueID>9107784</NlmUniqueID><ISSNLinking>0959-440X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000606290">SOD1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Disclosures. The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>11</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>11</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>12</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>1</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>1</Month><Day>19</Day><Hour>20</Hour><Minute>9</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33465527</ArticleId><ArticleId IdType="mid">NIHMS1658605</ArticleId><ArticleId IdType="pmc">PMC7965251</ArticleId><ArticleId IdType="doi">10.1016/j.sbi.2020.12.002</ArticleId><ArticleId IdType="pii">S0959-440X(20)30218-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Grad LI, Rouleau GA, Ravits J, Cashman NR: Clinical spectrum of amyotrophic lateral sclerosis (ALS). Cold Spring Harb Perspect Med 2017, 7:a024117.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5538408</ArticleId><ArticleId IdType="pubmed">28003278</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O, Al-Chalabi A, Chio A, Corr EM, Logroscino G, Robberecht W, Shaw PJ, Simmons Z, van den Berg LH: Amyotrophic lateral sclerosis. Nat Rev Dis Prim 2017, 3:17071.</Citation><ArticleIdList><ArticleId IdType="pubmed">28980624</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Hardiman O: The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neurol 2013, 9:617&#x2013;628.</Citation><ArticleIdList><ArticleId IdType="pubmed">24126629</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejzini R, Flynn LL, Pitout IL, Fletcher S, Wilton SD, Akkari PA: ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now?. Front Neurosci 2019, 13:1310.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6909825</ArticleId><ArticleId IdType="pubmed">31866818</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, Burrell JR, Zoing MC: Amyotrophic lateral sclerosis. Lancet 2011, 377:942&#x2013;955.</Citation><ArticleIdList><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner D, Weishaupt JH: Update on amyotrophic lateral sclerosis genetics. Curr Opin Neurol 2019, 32:735&#x2013;739.</Citation><ArticleIdList><ArticleId IdType="pubmed">31335339</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghasemi M, Brown RH: Genetics of amyotrophic lateral sclerosis. Cold Spring Harb Perspect Med 2018, 8:a024125.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5932579</ArticleId><ArticleId IdType="pubmed">28270533</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Battistini S, Calvo A, Caponnetto C, Conforti FL, Corbo M, Giannini F, Mandrioli J, Mora G, Sabatelli M: Genetic counselling in ALS: facts, uncertainties and clinical suggestions. J Neurol Neurosurg Psychiatry 2014, 85:478&#x2013;485.</Citation><ArticleIdList><ArticleId IdType="pubmed">23833266</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, Donaldson D, Goto J, O&#x2019;Regan JP, Deng H-X: Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 1993, 362:59&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Proctor EA, Fee L, Tao Y, Redler RL, Fay JM, Zhang Y, Lv Z, Mercer IP, Deshmukh M, Lyubchenko YL, et al.: Nonnative SOD1 trimer is toxic to motor neurons in a model of amyotrophic lateral sclerosis. Proc Natl Acad Sci 2016, 113:614 LP&#x2013;619.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4725519</ArticleId><ArticleId IdType="pubmed">26719414</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu C, Beck MV, Griffith JD, Deshmukh M, Dokholyan NV: Large SOD1 aggregates, unlike trimeric SOD1, do not impact cell viability in a model of amyotrophic lateral sclerosis. Proc Natl Acad Sci 2018, 115:4661 LP&#x2013;4665.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5939103</ArticleId><ArticleId IdType="pubmed">29666246</ArticleId></ArticleIdList></Reference><Reference><Citation>Gill C, Phelan JP, Hatzipetros T, Kidd JD, Tassinari VR, Levine B, Wang MZ, Moreno A, Thompson K, Maier M: SOD1-positive aggregate accumulation in the CNS predicts slower disease progression and increased longevity in a mutant SOD1 mouse model of ALS. Sci Rep 2019, 9:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6491559</ArticleId><ArticleId IdType="pubmed">31040321</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirvanyants D, Redler RL, Tandon A, Kim DN, Dagliyan O, Proctor EA, Dokholyan NV, Kota P, Ramachandran S, Ding F: Computational approaches to understanding protein aggregation in neurodegeneration. J Mol Cell Biol 2014, 6:104&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3995224</ArticleId><ArticleId IdType="pubmed">24620031</ArticleId></ArticleIdList></Reference><Reference><Citation>Redler RL, Dokholyan NV: The complex molecular biology of amyotrophic lateral sclerosis (ALS). In Progress in molecular biology and translational science. Elsevier; 2012:215&#x2013;262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3605887</ArticleId><ArticleId IdType="pubmed">22482452</ArticleId></ArticleIdList></Reference><Reference><Citation>Medinas DB, Gozzo FC, Santos LFA, Iglesias AH, Augusto O: A ditryptophan cross-link is responsible for the covalent dimerization of human superoxide dismutase 1 during its bicarbonate-dependent peroxidase activity. Free Radic Biol Med 2010, 49:1046&#x2013;1053.</Citation><ArticleIdList><ArticleId IdType="pubmed">20600836</ArticleId></ArticleIdList></Reference><Reference><Citation>Workman A: Nucleation and kinetics of SOD1 aggregation in human cells for ALS1. Mol Cell Biochem 2020, 466:117&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pubmed">32056106</ArticleId></ArticleIdList></Reference><Reference><Citation>Sala FA, Wright GSA, Antonyuk SV, Garratt RC, Hasnain SS: Molecular recognition and maturation of SOD1 by its evolutionarily destabilised cognate chaperone hCCS. PLoS Biol 2019, 17:e3000141.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6383938</ArticleId><ArticleId IdType="pubmed">30735496</ArticleId></ArticleIdList></Reference><Reference><Citation>Khare SD, Caplow M, Dokholyan NV: The rate and equilibrium constants for a multistep reaction sequence for the aggregation of superoxide dismutase in amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 2004, 101:15094 LP&#x2013;15099.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC524068</ArticleId><ArticleId IdType="pubmed">15475574</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilcox KC, Zhou L, Jordon JK, Huang Y, Yu Y, Redler RL, Chen X, Caplow M, Dokholyan NV: Modifications of superoxide dismutase (sod1) in human erythrocytes a possible role in amyotrophic lateral sclerosis. J Biol Chem 2009, 284:13940&#x2013;13947.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2679493</ArticleId><ArticleId IdType="pubmed">19299510</ArticleId></ArticleIdList></Reference><Reference><Citation>Proctor EA, Mowrey DD, Dokholyan NV: &#x3b2;-Methylamino-L-alanine substitution of serine in SOD1 suggests a direct role in ALS etiology. PLOS Comput Biol 2019, 15:e1007225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6668853</ArticleId><ArticleId IdType="pubmed">31323035</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrozziello T, Secondo A, Tedeschi V, Esposito A, Sisalli M, Scorziello A, Di Renzo G, Annunziato L: ApoSOD1 lacking dismutase activity neuroprotects motor neurons exposed to beta-methylamino-L-alanine through the Ca2+/Akt/ERK1/2 prosurvival pathway. Cell Death Differ 2017, 24:511&#x2013;522.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5344211</ArticleId><ArticleId IdType="pubmed">28085149</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaur SJ, McKeown SR, Rashid S: Mutant SOD1 mediated pathogenesis of amyotrophic lateral sclerosis. Gene 2016, 577:109&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">26657039</ArticleId></ArticleIdList></Reference><Reference><Citation>Chao W-C, Lu J-F, Wang J-S, Chiang T-H, Lin L-J, Lee Y-L, Chou P-T: Unveiling the structural features of nonnative trimers of human superoxide dismutase 1. Biochim Biophys Acta (BBA)-General Subj 2020, 1864:129483.</Citation><ArticleIdList><ArticleId IdType="pubmed">31734464</ArticleId></ArticleIdList></Reference><Reference><Citation>Srinivasan E, Rajasekaran R: Cysteine to serine conversion at 111th position renders the disaggregation and retains the stabilization of detrimental SOD1 A4V mutant against amyotrophic lateral sclerosis in human&#x2014;a discrete molecular dynamics study. Cell Biochem Biophys 2018, 76:231&#x2013;241.</Citation><ArticleIdList><ArticleId IdType="pubmed">28952073</ArticleId></ArticleIdList></Reference><Reference><Citation>Bille A, Jensen KS, Mohanty S, Akke M, Irb&#xe4;ck A: Stability and local unfolding of SOD1 in the presence of protein crowders. J Phys Chem B 2019, 123:1920&#x2013;1930.</Citation><ArticleIdList><ArticleId IdType="pubmed">30753785</ArticleId></ArticleIdList></Reference><Reference><Citation>Pokrishevsky E, Hong RH, Mackenzie IR, Cashman NR: Spinal cord homogenates from SOD1 familial amyotrophic lateral sclerosis induce SOD1 aggregation in living cells. PLoS One 2017, 12:e0184384.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5587256</ArticleId><ArticleId IdType="pubmed">28877271</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;nch C, O&#x2019;Brien J, Bertolotti A: Prion-like propagation of mutant superoxide dismutase-1 misfolding in neuronal cells. Proc Natl Acad Sci 2011, 108:3548&#x2013;3553.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3048161</ArticleId><ArticleId IdType="pubmed">21321227</ArticleId></ArticleIdList></Reference><Reference><Citation>McAlary L, Plotkin SS, Yerbury JJ, Cashman N: Prion-like propagation of protein misfolding and aggregation in amyotrophic lateral sclerosis. Front Mol Neurosci 2019, 12:262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6838634</ArticleId><ArticleId IdType="pubmed">31736708</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayers JI, Fromholt SE, O&#x2019;Neal VM, Diamond JH, Borchelt DR: Prion-like propagation of mutant SOD1 misfolding and motor neuron disease spread along neuroanatomical pathways. Acta Neuropathol 2016, 131:103&#x2013;114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4699876</ArticleId><ArticleId IdType="pubmed">26650262</ArticleId></ArticleIdList></Reference><Reference><Citation>Dagan B, Oren O, Banerjee V, Taube R, Papo N: A hyperthermophilic protein G variant engineered via directed evolution prevents the formation of toxic SOD1 oligomers. Proteins Struct Funct Bioinforma 2019, 87:738&#x2013;747.</Citation><ArticleIdList><ArticleId IdType="pubmed">31017342</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright GSA: Molecular and pharmacological chaperones for SOD1. Biochem Soc Trans 2020, 48:1795&#x2013;1806.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7458393</ArticleId><ArticleId IdType="pubmed">32794552</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y, Park J-H, Jang J-Y, Rhim H, Kang S: Characterization and Hsp104-induced artificial clearance of familial ALS-related SOD1 aggregates. Biochem Biophys Res Commun 2013, 434:521&#x2013;526.</Citation><ArticleIdList><ArticleId IdType="pubmed">23583391</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolozin B, Ivanov P: Stress granules and neurodegeneration. Nat Rev Neurosci 2019, 20:649&#x2013;666.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6986315</ArticleId><ArticleId IdType="pubmed">31582840</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernandes N, Eshleman N, Buchan JR: Stress granules and ALS: a case of causation or correlation? In RNA Metabolism in Neurodegenerative Diseases. Springer; 2018:173&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pubmed">29916020</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee D-Y, Jeon GS, Sung J-J: ALS-Linked Mutant SOD1 Associates with TIA-1 and Alters Stress Granule Dynamics. Neurochem Res 2020, doi:10.1007/s11064-020-03137-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-020-03137-5</ArticleId><ArticleId IdType="pubmed">33025330</ArticleId></ArticleIdList></Reference><Reference><Citation>Da Ros M, Deol HK, Savard A, Guo H, Meiering EM, Gibbings D: Wild-type and mutant SOD1 localizes to RNA-rich structures in cells and mice but does not bind RNA. J Neurochem 2020,</Citation><ArticleIdList><ArticleId IdType="pubmed">32683701</ArticleId></ArticleIdList></Reference><Reference><Citation>Zetterstr&#xf6;m P, Stewart HG, Bergemalm D, Jonsson PA, Graffmo KS, Andersen PM, Br&#xe4;nnstr&#xf6;m T, Oliveberg M, Marklund SL: Soluble misfolded subfractions of mutant superoxide dismutase-1s are enriched in spinal cords throughout life in murine ALS models. Proc Natl Acad Sci 2007, 104:14157&#x2013;14162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1955813</ArticleId><ArticleId IdType="pubmed">17715066</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholson K, Murphy A, McDonnell E, Shapiro J, Simpson E, Glass J, Mitsumoto H, Forshew D, Miller R, Atassi N: Improving symptom management for people with amyotrophic lateral sclerosis. Muscle Nerve 2018, 57:20&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">28561886</ArticleId></ArticleIdList></Reference><Reference><Citation>Niedermeyer S, Murn M, Choi PJ: Respiratory Failure in Amyotrophic Lateral Sclerosis. Chest 2019, 155:401&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="pubmed">29990478</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E, Traynor BG, Consortium OB of the E: Prognostic factors in ALS: A critical review. Amyotroph Lateral Scler 2009, 10:310&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3515205</ArticleId><ArticleId IdType="pubmed">19922118</ArticleId></ArticleIdList></Reference><Reference><Citation>Bensimon G, Lacomblez L, Meininger V: A Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis. N Engl J Med 1994, 330:585&#x2013;591.</Citation><ArticleIdList><ArticleId IdType="pubmed">8302340</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein JD: Edaravone: a new drug approved for ALS. Cell 2017, 171:725.</Citation><ArticleIdList><ArticleId IdType="pubmed">29100067</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaiswal MK: Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs. Med Res Rev 2019, 39:733&#x2013;748.</Citation><ArticleIdList><ArticleId IdType="pubmed">30101496</ArticleId></ArticleIdList></Reference><Reference><Citation>Fay JM, Zhu C, Proctor EA, Tao Y, Cui W, Ke H, Dokholyan NV: A phosphomimetic mutation stabilizes SOD1 and rescues cell viability in the context of an ALS-associated mutation. Structure 2016, 24:1898&#x2013;1906.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5093072</ArticleId><ArticleId IdType="pubmed">27667694</ArticleId></ArticleIdList></Reference><Reference><Citation>Redler RL, Fee L, Fay JM, Caplow M, Dokholyan NV: Non-native Soluble Oligomers of Cu/Zn Superoxide Dismutase (SOD1) Contain a Conformational Epitope Linked to Cytotoxicity in Amyotrophic Lateral Sclerosis (ALS). Biochemistry 2014, 53:2423&#x2013;2432.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4004233</ArticleId><ArticleId IdType="pubmed">24660965</ArticleId></ArticleIdList></Reference><Reference><Citation>Shvil N, Banerjee V, Zoltsman G, Shani T, Kahn J, Abu-Hamad S, Papo N, Engel S, Bernhagen J, Israelson A: MIF inhibits the formation and toxicity of misfolded SOD1 amyloid aggregates: implications for familial ALS. Cell Death Dis 2018, 9:1&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5833700</ArticleId><ArticleId IdType="pubmed">29371591</ArticleId></ArticleIdList></Reference><Reference><Citation>Tateno M, Sadakata H, Tanaka M, Itohara S, Shin R-M, Miura M, Masuda M, Aosaki T, Urushitani M, Misawa H: Calcium-permeable AMPA receptors promote misfolding of mutant SOD1 protein and development of amyotrophic lateral sclerosis in a transgenic mouse model. Hum Mol Genet 2004, 13:2183&#x2013;2196.</Citation><ArticleIdList><ArticleId IdType="pubmed">15294873</ArticleId></ArticleIdList></Reference><Reference><Citation>Atlasi RS, Malik R, Corrales CI, Tzeplaeff L, Whitelegge JP, Cashman NR, Bitan G: Investigation of anti-SOD1 antibodies yields new structural insight into SOD1 misfolding and surprising behavior of the antibodies themselves. ACS Chem Biol 2018, 13:2794&#x2013;2807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6475120</ArticleId><ArticleId IdType="pubmed">30110532</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Zhang J, Wang Y, Feng Y, Zhang X, Sun X, Li J, Du X, Lambert MP, Yang S: Conformation-dependent single-chain variable fragment antibodies specifically recognize beta-amyloid oligomers. FEBS Lett 2009, 583:579&#x2013;584.</Citation><ArticleIdList><ArticleId IdType="pubmed">19162022</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong Q, Zhu J, Liu S, Yu X, Liu R: An oligomer-specific antibody improved motor function and attenuated neuropathology in the SOD1-G93A transgenic mouse model of ALS. Int Immunopharmacol 2018, 65:413&#x2013;421.</Citation><ArticleIdList><ArticleId IdType="pubmed">30388515</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrov D, Mansfield C, Moussy A, Hermine O: ALS clinical trials review: 20 years of failure. Are we any closer to registering a new treatment? Front Aging Neurosci 2017, 9:68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5360725</ArticleId><ArticleId IdType="pubmed">28382000</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>